Pietro Del Medico

TL;DR: GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.

TL;DR: Carboplatin/PLD was not superior to carboplarin/paclitaxel, which remains the standard first-line chemotherapy for advanced ovarian cancer, however, given the observed CIs and the different toxicity, carboplatin-PLD could be considered an alternative to standard therapy.

TL;DR: The hypothesis that the addition of pertuzumab to trastuzumAB reduces the amount of available plasma membrane HER2 receptor, limiting the binding of T-DM1 in cancer cells is supported.

TL;DR: In this paper, the authors address the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER 2 positivity when relapsed, and they suggest that patients with HER2-positive mBC with discordant HER 2 status in early BC may have different clinical, biological and prognostic behavior compared to HER2concordant patients.

TL;DR: In this cohort, a BMI ≥ 30 correlated with worse OS in patients with HER2+ mBC who received pertuzumab and/or T‐DM1 but had no impact on PFS to first line, and BMI predicted worse I PFS1 quartile.